HC2 ANNOUNCES PANSEND LIFE SCIENCES PORTFOLIO COMPANY BENEVIR BIOPHARM TO BE ACQUIRED BY JANSSEN BIOTECH, INC. FOR UP TO $1.04 BILLION
HC2 Holdings, Inc. (“HC2”) (NYSE:HCHC), a diversified holding company, announced today that BeneVir Biopharm, Inc. (“BeneVir”), a privately-held biotechnology company developing oncolytic immunotherapies for the treatment of cancer, has entered into a definitive agreement to be acquired by Janssen Biotech, Inc. (“Janssen”).